Rise Therapeutics’ Post

It’s so rewarding knowing that with your work, you can make a difference in the lives of people living with a rare disease. With our marketing efforts, we aim to increase awareness of the disease, improve diagnosis, and ensure patients in need have access to this first available treatment in Europe. Because every single life counts. #rewards #marketing #healthcare #rarediseases #diagnosis

Listen to Optimum Strategic Communications latest podcast around #clinicaltrials

Check out Optimum's latest podcast featuring an expert panel discussing the issue of diversity in clinical trial recruitment. Thanks to Germo Gericke, Annalisa Jenkins and John Maher for taking part!

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

This is an impressive application of decision-quality principles very early in biopharma R&D.

New article published in Drug Discovery Today: Making Good Decisions in Early Drug Discovery Our team is excited to share a new article co-authored by Martin Stahl (LifeMine Therapeutics), Virginie Sandrin (Roche), and Bigna Wörsdörfer (Roche) with Ellen Coopersmith and Samuel Vardy of Decision Frameworks.  The article shares a proven and effective Decision Quality approach that guides collaborative team discussions to generate alternative discovery advancement plans and qualitatively assess them. The product is a clear decision roadmap for the team to follow and readjust as research progresses.  Read the full article here: https://lnkd.in/g_-h2gRq     #DecisionMaking #DecisionQuality #DrugDiscovery #Strategy #Uncertainty 

Eli lilly Acquires Morphic Therapeutic for $3.2B 🤝 👉 Eli Lilly will acquire Morphic Holding, a Massachusetts-based biotech company, for $3.2 billion, securing access to an experimental inflammatory bowel disease drug. 👉 Morphic's shares surged 76% pre-market to $56.15 on Lilly's $57 per share offer, a 79% premium to the last closing price. 👉 Morphic's lead drug, MORF-057, is in phase 2 studies for ulcerative colitis and Crohn's disease. The acquisition strengthens Lilly's pipeline in the inflammatory bowel disease treatment market. 💊

Hot of the Press! It’s been publications galore in the RAS world in 2024 and the past week has been no exception. Luckily enough, first and best-in-class therapies for CRC, pan-RAS approaches and non-canonical targets will be the hot topics filled with BRAND NEW DATA, exclusively at the 6th Annual RAS-Targeted Drug Development Summit (September 24 – 26, Boston, MA). Peers from Revolution Medicines, Amgen, Loxo@Lilly, Roche, GenFleet Therapeutics, Nested Therapeutics, Astellas Pharma, and 40+ more organizations are uniting to improve the standard of care for patients with unmet needs. Download the brochure now to see our topics of choice and find out how to join them: https://ter.li/8vhngl References: https://lnkd.in/eqznq5rM https://lnkd.in/eHYFStQE

As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY